MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
3.450
+0.100
+2.99%
Opening 11:01 03/31 EDT
OPEN
3.390
PREV CLOSE
3.350
HIGH
3.450
LOW
3.370
VOLUME
508
TURNOVER
1.72K
52 WEEK HIGH
4.850
52 WEEK LOW
2.330
MARKET CAP
40.14M
P/E (TTM)
-3.0947
1D
5D
1M
3M
1Y
5Y
Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP)
TipRanks · 03/17 14:40
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), TFF Pharmaceuticals (TFFP) and Acurx Pharmaceuticals (ACXP)
TipRanks · 03/17 10:40
BRIEF-Acurx Pharmaceuticals-Filed Protocol Amendment To Ind With FDA To Allow For Idmc To Review Interim Clinical Data From Ongoing Phase 2B Clinical Trial
Reuters · 03/16 11:35
Acurx Pharmaceuticals GAAP EPS of -$0.28 beats by $0.15
Seeking Alpha · 03/16 11:10
Acurx Pharmaceuticals Q4 EPS $(0.28) Beats $(0.35) Estimate; Cash Position Of $9.1M
Benzinga · 03/16 11:08
BRIEF-Acurx Pharmaceuticals Reports Fourth Quarter Results
Reuters · 03/16 11:03
Earnings Scheduled For March 16, 2023
Benzinga · 03/16 10:59
Acurx Pharmaceuticals's Earnings: A Preview
Benzinga · 03/15 16:02
More
About ACXP
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). The Company develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. The Company’s research and development pipeline includes clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile; Enterococcus, including vancomycin-resistant strain; Staphylococcus, including methicillin-resistant strains, and Streptococcus, including antibiotic resistant strains).

Webull offers kinds of Acurx Pharmaceuticals Inc stock information, including NASDAQ:ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.